Association among genetic predisposition, gut microbiota, and host immune response in the etiopathogenesis of inflammatory bowel disease

Brazilian Journal of Medical and Biological Research

Volumn 47, Issue 9, 2014, Pages 727-737

  Basso, P J ^a   Fonseca, M T C ^a   Bonfa G ^a   Alves, V B F ^a   Sales Campos, H ^a   Nardini, V ^a   Cardoso, C R B ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Crohn's disease; Etiology; Immune response; Inflammatory bowel disease; Microbiota; Ulcerative colitis

Indexed keywords

CASPASE RECRUITMENT DOMAIN PROTEIN 15; CHEMOKINE RECEPTOR CCR6; CRYOPYRIN; INTERLEUKIN 12; INTERLEUKIN 23; THYMIC STROMAL LYMPHOPOIETIN; TOLL LIKE RECEPTOR; UVOMORULIN;

DENDRITIC CELL; DYSBIOSIS; ENVIRONMENTAL FACTOR; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; HUMAN; IMMUNE RESPONSE; INFLAMMATION; INFLAMMATORY BOWEL DISEASE; INTESTINE EPITHELIUM CELL; INTESTINE FLORA; LYMPHOID CELL; MACROPHAGE; NONHUMAN; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; REVIEW; ULCERATIVE COLITIS; ANIMAL; GASTROINTESTINAL TRACT; GENETICS; GENOTYPE ENVIRONMENT INTERACTION; HOST PATHOGEN INTERACTION; IMMUNOLOGY; INFLAMMATORY BOWEL DISEASES; INTESTINE MUCOSA; MICROBIOLOGY; MICROFLORA;

ANIMALS; GASTROINTESTINAL TRACT; GENE-ENVIRONMENT INTERACTION; GENETIC PREDISPOSITION TO DISEASE; HOST-PATHOGEN INTERACTIONS; HUMANS; INFLAMMATORY BOWEL DISEASES; INTESTINAL MUCOSA; MICROBIOTA; POLYMORPHISM, GENETIC;

EID: 84906485586     PISSN: 0100879X     EISSN: 1414431X     Source Type: Journal    
DOI: 10.1590/1414-431X20143932     Document Type: Review

References (90)

1. Ng SC, Bernstein CN, Vatn MH, Lakatos PL, Loftus EV Jr, Tysk C, et al. Geographical variability and environmental risk factors in inflammatory bowel disease. Gut 2013; 62: 630-649, doi: 10.1136/gutjnl-2012-303661.
2. Victoria CR, Sassak LY, Nunes H.R. Incidence and prevalence rates of inflammatory bowel diseases, in midwestern of São Paulo State, Brazil. Arq Gastroenterol 2009; 46: 20-25, doi: 10.1590/S0004-28032009000100009.
3. De Jager PL, Franchimont D, Waliszewska A, Bitton A, Cohen A, Langelier D, et al. The role of the Toll receptor pathway in susceptibility to inflammatory bowel diseases. Genes Immun 2007; 8: 387-397, doi: 10.1038/sj.gene. 6364398.
4. Pierik M, Joossens S, Van Steen K, Van Schuerbeek N, Vlietinck R, Rutgeerts P, et al. Toll-like receptor-1,-2, and-6 polymorphisms influence disease extension in inflammatory bowel diseases. Inflamm Bowel Dis 2006; 12: 1-8, doi: 10.1097/01.MIB.0000195389.11645.ab.
5. Hugot JP, Chamaillard M, Zouali H, Lesage S, Cezard JP, Belaiche J, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 2001; 411: 599-603, doi: 10.1038/35079107.
6. Anderson CA, Boucher G, Lees CW, Franke A, D'Amato M, Taylor KD, et al. Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nat Genet 2011; 43: 246-252, doi: 10.1038/ng.764.
7. Franke A, McGovern DP, Barrett JC, Wang K, Radford-Smith GL, Ahmad T, et al. Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nat Genet 2010; 42: 1118-1125, doi: 10.1038/ng.717.
8. Wehkamp J, Harder J, Weichenthal M, Schwab M, Schaffeler E, Schlee M, et al. NOD2 (CARD15) mutations in Crohn's disease are associated with diminished mucosal alpha-defensin expression. Gut 2004; 53: 1658-1664, doi: 10.1136/gut.2003.032805.
9. Villani AC, Lemire M, Fortin G, Louis E, Silverberg MS, Collette C, et al. Common variants in the NLRP3 region contribute to Crohn's disease susceptibility. Nat Genet 2009; 41: 71-76, doi: 10.1038/ng.285.
10. Palomino-Morales RJ, Oliver J, Gomez-Garcia M, Lopez-Nevot MA, Rodrigo L, Nieto A, et al. Association of ATG16L1 and IRGM genes polymorphisms with inflammatory bowel disease: a meta-analysis approach. Genes Immun 2009; 10: 356-364, doi: 10.1038/gene.2009.25.
11. Barrett JC, Hansoul S, Nicolae DL, Cho JH, Duerr RH, Rioux JD, et al. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat Genet 2008; 40: 955-962, doi: 10.1038/ng.175.
12. Glas J, Wagner J, Seiderer J, Olszak T, Wetzke M, Beigel F, et al. PTPN2 gene variants are associated with susceptibility to both Crohn's disease and ulcerative colitis supporting a common genetic disease background. PLoS One 2012; 7: e33682, doi: 10.1371/journal.pone.0033682.
13. Rausch P, Rehman A, Kunzel S, Hasler R, Ott SJ, Schreiber S, et al. Colonic mucosa-associated microbiota is influenced by an interaction of Crohn disease and FUT2 (Secretor) genotype. Proc Natl Acad Sci U S A 2011; 108: 19030-19035, doi: 10.1073/pnas.1106408108.
14. Ott SJ, Musfeldt M, Wenderoth DF, Hampe J, Brant O, Folsch UR, et al. Reduction in diversity of the colonic mucosa associated bacterial microflora in patients with active inflammatory bowel disease. Gut 2004; 53: 685-693, doi: 10.1136/gut.2003.025403.
15. Walker AW, Sanderson JD, Churcher C, Parkes GC, Hudspith BN, Rayment N, et al. High-throughput clone library analysis of the mucosa-associated microbiota reveals dysbiosis and differences between inflamed and non-inflamed regions of the intestine in inflammatory bowel disease. BMC Microbiol 2011; 11: 7, doi: 10.1186/1471-2180-11-7.
16. Willing B, Halfvarson J, Dicksved J, Rosenquist M, Jarnerot G, Engstrand L, et al. Twin studies reveal specific imbalances in the mucosa-associated microbiota of patients with ileal Crohn's disease. Inflamm Bowel Dis 2009; 15: 653-660, doi: 10.1002/ibd.20783.
17. Frank DN, Robertson CE, Hamm CM, Kpadeh Z, Zhang T, Chen H, et al. Disease phenotype and genotype are associated with shifts in intestinal-associated microbiota in inflammatory bowel diseases. Inflamm Bowel Dis 2011; 17: 179-184, doi: 10.1002/ibd.21339.
18. Wehkamp J, Salzman NH, Porter E, Nuding S, Weichenthal M, Petras RE, et al. Reduced Paneth cell alpha-defensins in ileal Crohn's disease. Proc Natl Acad Sci U S A 2005; 102: 18129-18134, doi: 10.1073/pnas.0505256102.
19. Tamboli CP, Neut C, Desreumaux P, Colombel J.F. Dysbiosis in inflammatory bowel disease. Gut 2004; 53: 1-4, doi: 10.1136/gut.53.1.1.
20. Rooks MG, Veiga P, Wardwell-Scott LH, Tickle T, Segata N, Michaud M, et al. Gut microbiome composition and function in experimental colitis during active disease and treatmentinduced remission. ISME J 2014.
21. Swidsinski A, Weber J, Loening-Baucke V, Hale LP, Lochs H. Spatial organization and composition of the mucosal flora in patients with inflammatory bowel disease. J Clin Microbiol 2005; 43: 3380-3389, doi: 10.1128/JCM.43.7.3380-3389. 2005.
22. Gerding D.N. Clindamycin, cephalosporins, fluoroquinolones, and Clostridium difficile-associated diarrhea: this is an antimicrobial resistance problem. Clin Infect Dis 2004; 38: 646-648, doi: 10.1086/382084.
23. Furusawa Y, Obata Y, Fukuda S, Endo TA, Nakato G, Takahashi D, et al. Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. Nature 2013; 504: 446-450, doi: 10.1038/nature12721.
24. Arpaia N, Campbell C, Fan X, Dikiy S, van der Veeken J, deRoos P, et al. Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation. Nature 2013; 504: 451-455, doi: 10.1038/nature12726.
25. Ivanov II, Atarashi K, Manel N, Brodie EL, Shima T, Karaoz U, et al. Induction of intestinal Th17 cells by segmented filamentous bacteria. Cell 2009; 139: 485-498, doi: 10.1016/j.cell.2009.09.033.
26. Salzman NH, Hung K, Haribhai D, Chu H, Karlsson-Sjoberg J, Amir E, et al. Enteric defensins are essential regulators of intestinal microbial ecology. Nat Immunol 2010; 11: 76-83, doi: 10.1038/ni.1825.
27. Qiu J, Guo X, Chen ZM, He L, Sonnenberg GF, Artis D, et al. Group 3 innate lymphoid cells inhibit T-cell-mediated intestinal inflammation through aryl hydrocarbon receptor signaling and regulation of microflora. Immunity 2013; 39: 386-399, doi: 10.1016/j.immuni.2013.08.002.
28. Maloy KJ, Powrie F. Intestinal homeostasis and its breakdown in inflammatory bowel disease. Nature 2011; 474: 298-306, doi: 10.1038/nature10208.
29. Gerova VA, Stoynov SG, Katsarov DS, Svinarov D.A. Increased intestinal permeability in inflammatory bowel diseases assessed by iohexol test. World J Gastroenterol 2011; 17: 2211-2215, doi: 10.3748/wjg.v17.i17.
30. Kiesslich R, Duckworth CA, Moussata D, Gloeckner A, Lim LG, Goetz M, et al. Local barrier dysfunction identified by confocal laser endomicroscopy predicts relapse in inflammatory bowel disease. Gut 2012; 61: 1146-1153, doi: 10.1136/gutjnl-2011-300695.
31. Mankertz J, Tavalali S, Schmitz H, Mankertz A, Riecken EO, Fromm M, et al. Expression from the human occludin promoter is affected by tumor necrosis factor alpha and interferon gamma. J Cell Sci 2000; 113 (Part 11): 2085-2090.
32. Suzuki T, Yoshinaga N, Tanabe S. Interleukin-6 (IL-6) regulates claudin-2 expression and tight junction permeability in intestinal epithelium. J Biol Chem 2011; 286: 31263-31271, doi: 10.1074/jbc.M111.238147.
33. Buisine MP, Desreumaux P, Leteurtre E, Copin MC, Colombel JF, Porchet N, et al. Mucin gene expression in intestinal epithelial cells in Crohn's disease. Gut 2001; 49: 544-551, doi: 10.1136/gut.49.4.544.
34. Cario E, Podolsky D.K. Differential alteration in intestinal epithelial cell expression of toll-like receptor 3 (TLR3) and TLR4 in inflammatory bowel disease. Infect Immun 2000; 68: 7010-7017, doi: 10.1128/IAI.68.12.7010-7017.2000.
35. Pedersen G, Andresen L, Matthiessen MW, Rask-Madsen J, Brynskov J. Expression of Toll-like receptor 9 and response to bacterial CpG oligodeoxynucleotides in human intestinal epithelium. Clin Exp Immunol 2005; 141: 298-306, doi: 10.1111/j.1365-2249.2005.02848.x.
36. Hausmann M, Kiessling S, Mestermann S, Webb G, Spottl T, Andus T, et al. Toll-like receptors 2 and 4 are upregulated during intestinal inflammation. Gastroenterology 2002; 122: 1987-2000, doi: 10.1053/gast.2002.33662.
37. Fort MM, Mozaffarian A, Stover AG, Correia JS, Johnson DA, Crane RT, et al. A synthetic TLR4 antagonist has antiinflammatory effects in two murine models of inflammatory bowel disease. J Immunol 2005; 174: 6416-6423, doi: 10.4049/jimmunol.174.10.6416.
38. Torok HP, Glas J, Endres I, Tonenchi L, Teshome MY, Wetzke M, et al. Epistasis between Toll-like receptor-9 polymorphisms and variants in NOD2 and IL23R modulates susceptibility to Crohn's disease. Am J Gastroenterol 2009; 104: 1723-1733, doi: 10.1038/ajg.2009.184.
39. Cooney R, Baker J, Brain O, Danis B, Pichulik T, Allan P, et al. NOD2 stimulation induces autophagy in dendritic cells influencing bacterial handling and antigen presentation. Nat Med 2010; 16: 90-97, doi: 10.1038/nm.2069.
40. Jiang W, Wang X, Zeng B, Liu L, Tardivel A, Wei H, et al. Recognition of gut microbiota by NOD2 is essential for the homeostasis of intestinal intraepithelial lymphocytes. J Exp Med 2013; 210: 2465-2476, doi: 10.1084/jem.20122490.
41. Couturier-Maillard A, Secher T, Rehman A, Normand S, De AA, Haesler R, et al. NOD2-mediated dysbiosis predisposes mice to transmissible colitis and colorectal cancer. J Clin Invest 2013; 123: 700-711.
42. Amendola A, Butera A, Sanchez M, Strober W, Boirivant M. Nod2 deficiency is associated with an increased mucosal immunoregulatory response to commensal microorganisms. Mucosal Immunol 2014; 7: 391-404, doi: 10.1038/mi. 2013.58.
43. Niess JH, Brand S, Gu X, Landsman L, Jung S, McCormick BA, et al. CX3CR1-mediated dendritic cell access to the intestinal lumen and bacterial clearance. Science 2005; 307: 254-258, doi: 10.1126/science.1102901.
44. Varol C, Zigmond E, Jung S. Securing the immune tightrope: mononuclear phagocytes in the intestinal lamina propria. Nat Rev Immunol 2010; 10: 415-426, doi: 10.1038/nri2778.
45. Annacker O, Coombes JL, Malmstrom V, Uhlig HH, Bourne T, Johansson-Lindbom B, et al. Essential role for CD103 in the T cell-mediated regulation of experimental colitis. J Exp Med 2005; 202: 1051-1061, doi: 10.1084/jem.20040662.
46. Siddiqui KR, Laffont S, Powrie F. E-cadherin marks a subset of inflammatory dendritic cells that promote T cell-mediated colitis. Immunity 2010; 32: 557-567, doi: 10.1016/j.immuni.2010.03.017.
47. Baumgart DC, Thomas S, Przesdzing I, Metzke D, Bielecki C, Lehmann SM, et al. Exaggerated inflammatory response of primary human myeloid dendritic cells to lipopolysaccharide in patients with inflammatory bowel disease. Clin Exp Immunol 2009; 157: 423-436, doi: 10.1111/j.1365-2249. 2009.03981.x.
48. Cai Z, Zhang W, Li M, Yue Y, Yang F, Yu L, et al. TGFbeta1 gene-modified, immature dendritic cells delay the development of inflammatory bowel disease by inducing CD4(+)Foxp3(+) regulatory T cells. Cell Mol Immunol 2010; 7: 35-43, doi: 10.1038/cmi.2009.107.
49. Bain CC, Scott CL, Uronen-Hansson H, Gudjonsson S, Jansson O, Grip O, et al. Resident and pro-inflammatory macrophages in the colon represent alternative contextdependent fates of the same Ly6Chi monocyte precursors. Mucosal Immunol 2013; 6: 498-510, doi: 10.1038/mi. 2012.89.
50. Schenk M, Bouchon A, Seibold F, Mueller C. TREM-1-expressing intestinal macrophages crucially amplify chronic inflammation in experimental colitis and inflammatory bowel diseases. J Clin Invest 2007; 117: 3097-3106, doi: 10.1172/JCI30602.
51. Liu Z, Yang L, Cui Y, Wang X, Guo C, Huang Z, et al. Il-21 enhances NK cell activation and cytolytic activity and induces Th17 cell differentiation in inflammatory bowel disease. Inflamm Bowel Dis 2009; 15: 1133-1144, doi: 10.1002/ibd.20923.
52. Takayama T, Kamada N, Chinen H, Okamoto S, Kitazume MT, Chang J, et al. Imbalance of NKp44(+)NKp46(-) and NKp44(-)NKp46(+) natural killer cells in the intestinal mucosa of patients with Crohn's disease. Gastroenterology 2010; 139: 882-92, 892, doi: 10.1053/j.gastro. 2010.05.040.
53. Cupedo T, Crellin NK, Papazian N, Rombouts EJ, Weijer K, Grogan JL, et al. Human fetal lymphoid tissue-inducer cells are interleukin 17-producing precursors to RORC+ CD127+ natural killer-like cells. Nat Immunol 2009; 10: 66-74, doi: 10.1038/ni.1668.
54. Buonocore S, Ahern PP, Uhlig HH, Ivanov II, Littman DR, Maloy KJ, et al. Innate lymphoid cells drive interleukin-23-dependent innate intestinal pathology. Nature 2010; 464: 1371-1375, doi: 10.1038/nature08949.
55. Lee JS, Cella M, McDonald KG, Garlanda C, Kennedy GD, Nukaya M, et al. AHR drives the development of gut ILC22 cells and postnatal lymphoid tissues via pathways dependent on and independent of Notch. Nat Immunol 2012; 13: 144-151, doi: 10.1038/ni.2187.
56. Sawa S, Lochner M, Satoh-Takayama N, Dulauroy S, Berard M, Kleinschek M, et al. RORgammat+ innate lymphoid cells regulate intestinal homeostasis by integrating negative signals from the symbiotic microbiota. Nat Immunol 2011; 12: 320-326, doi: 10.1038/ni.2002.
57. Zenewicz LA, Yancopoulos GD, Valenzuela DM, Murphy AJ, Stevens S, Flavell R.A. Innate and adaptive interleukin-22 protects mice from inflammatory bowel disease. Immunity 2008; 29: 947-957, doi: 10.1016/j.immuni. 2008.11.003.
58. Fuss IJ, Neurath M, Boirivant M, Klein JS, de la Motte C, Strong SA, et al. Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn's disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J Immunol 1996; 157: 1261-1270.
59. Verdier J, Begue B, Cerf-Bensussan N, Ruemmele F.M. Compartmentalized expression of Th1 and Th17 cytokines in pediatric inflammatory bowel diseases. Inflamm Bowel Dis 2012; 18: 1260-1266, doi: 10.1002/ibd.21905.
60. Neurath MF, Fuss I, Kelsall BL, Stuber E, Strober W. Antibodies to interleukin 12 abrogate established experimental colitis in mice. J Exp Med 1995; 182: 1281-1290, doi: 10.1084/jem.182.5.1281.
61. Oh SY, Cho KA, Kang JL, Kim KH, Woo S.Y. Comparison of experimental mouse models of inflammatory bowel disease. Int J Mol Med 2014; 33: 333-340.
62. Dige A, Stoy S, Rasmussen TK, Kelsen J, Hvas CL, Sandahl TD, et al. Increased levels of circulating Th17 cells in quiescent versus active Crohn's disease. J Crohns Colitis 2013; 7: 248-255, doi: 10.1016/j.crohns.2012.06.015.
63. Ito R, Kita M, Shin-Ya M, Kishida T, Urano A, Takada R, et al. Involvement of IL-17A in the pathogenesis of DSSinduced colitis in mice. Biochem Biophys Res Commun 2008; 377: 12-16, doi: 10.1016/j.bbrc.2008.09.019.
64. Fina D, Sarra M, Fantini MC, Rizzo A, Caruso R, Caprioli F, et al. Regulation of gut inflammation and th17 cell response by interleukin-21. Gastroenterology 2008; 134: 1038-1048, doi: 10.1053/j.gastro.2008.01.041.
65. Hue S, Ahern P, Buonocore S, Kullberg MC, Cua DJ, McKenzie BS, et al. Interleukin-23 drives innate and T cellmediated intestinal inflammation. J Exp Med 2006; 203: 2473-2483, doi: 10.1084/jem.20061099.
66. Elson CO, Cong Y, Weaver CT, Schoeb TR, McClanahan TK, Fick RB, et al. Monoclonal anti-interleukin 23 reverses active colitis in a T cell-mediated model in mice. Gastroenterology 2007; 132: 2359-2370, doi: 10.1053/j.gastro.2007.03.104.
67. Boniface K, Blumenschein WM, Brovont-Porth K, McGeachy MJ, Basham B, Desai B, et al. Human Th17 cells comprise heterogeneous subsets including IFNgamma-producing cells with distinct properties from the Th1 lineage. J Immunol 2010; 185: 679-687, doi: 10.4049/jimmunol.1000366.
68. Boirivant M, Fuss IJ, Chu A, Strober W. Oxazolone colitis: A murine model of T helper cell type 2 colitis treatable with antibodies to interleukin 4. J Exp Med 1998; 188: 1929-1939, doi: 10.1084/jem.188.10.1929.
69. Heller F, Fuss IJ, Nieuwenhuis EE, Blumberg RS, Strober W. Oxazolone colitis, a Th2 colitis model resembling ulcerative colitis, is mediated by IL-13-producing NK-T cells. Immunity 2002; 17: 629-638, doi: 10.1016/S1074-7613(02) 00453-3.
70. Liao CM, Zimmer MI, Shanmuganad S, Yu HT, Cardell SL, Wang C.R. dysregulation of CD1d-restricted type ii natural killer T cells leads to spontaneous development of colitis in mice. Gastroenterology 2012; 142: 326-334, doi: 10.1053/j.gastro.2011.10.030.
71. Fuss IJ, Heller F, Boirivant M, Leon F, Yoshida M, Fichtner-Feigl S, et al. Nonclassical CD1d-restricted NK T cells that produce IL-13 characterize an atypical Th2 response in ulcerative colitis. J Clin Invest 2004; 113: 1490-1497, doi: 10.1172/JCI19836.
72. Cebula A, Seweryn M, Rempala GA, Pabla SS, McIndoe RA, Denning TL, et al. Thymus-derived regulatory T cells contribute to tolerance to commensal microbiota. Nature 2013; 497: 258-262, doi: 10.1038/nature12079.
73. Mottet C, Uhlig HH, Powrie F. Cutting edge: cure of colitis by CD4+CD25+ regulatory T cells. J Immunol 2003; 170: 3939-3943, doi: 10.4049/jimmunol.170.8.3939.
74. Ishikawa D, Okazawa A, Corridoni D, Jia LG, Wang XM, Guanzon M, et al. Tregs are dysfunctional in vivo in a spontaneous murine model of Crohn's disease. Mucosal Immunol 2013; 6: 267-275, doi: 10.1038/mi.2012.67.
75. Powrie F, Carlino J, Leach MW, Mauze S, Coffman R.L. A critical role for transforming growth factor-beta but not interleukin 4 in the suppression of T helper type 1-mediated colitis by CD45RB(low) CD4+ T cells. J Exp Med 1996; 183: 2669-2674, doi: 10.1084/jem.183.6.2669.
76. Uhlig HH, Coombes J, Mottet C, Izcue A, Thompson C, Fanger A, et al. Characterization of Foxp3CD4+CD25+ and IL-10-secreting CD4+CD25+ T cells during cure of colitis. J Immunol 2006; 177: 5852-5860, doi: 10.4049/jimmunol.177.9.5852.
77. Gorelik L, Flavell R.A. Abrogation of TGFbeta signaling in T cells leads to spontaneous T cell differentiation and autoimmune disease. Immunity 2000; 12: 171-181, doi: 10.1016/S1074-7613(00)80170-3.
78. Fantini MC, Rizzo A, Fina D, Caruso R, Sarra M, Stolfi C, et al. Smad7 controls resistance of colitogenic T cells to regulatory T cell-mediated suppression. Gastroenterology 2009; 136: 1308-1316, doi: 10.1053/j.gastro.2008.12.053.
79. Kuhn R, Lohler J, Rennick D, Rajewsky K, Muller W. Interleukin-10-deficient mice develop chronic enterocolitis. Cell 1993; 75: 263-274, doi: 10.1016/0092-8674(93)80068-P.
80. Glocker EO, Kotlarz D, Boztug K, Gertz EM, Schaffer AA, Noyan F, et al. Inflammatory bowel disease and mutations affecting the interleukin-10 receptor. N Engl J Med 2009; 361: 2033-2045, doi: 10.1056/NEJMoa0907206.
81. Gambineri E, Perroni L, Passerini L, Bianchi L, Doglioni C, Meschi F, et al. Clinical and molecular profile of a new series of patients with immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome: inconsistent correlation between forkhead box protein 3 expression and disease severity. J Allergy Clin Immunol 2008; 122: 1105-1112, doi: 10.1016/j.jaci.2008.09.027.
82. Eastaff-Leung N, Mabarrack N, Barbour A, Cummins A, Barry S. Foxp3+ regulatory T cells, Th17 effector cells, and cytokine environment in inflammatory bowel disease. J Clin Immunol 2010; 30: 80-89, doi: 10.1007/s10875-009-9345-1.
83. Ueno A, Jijon H, Chan R, Ford K, Hirota C, Kaplan GG, et al. Increased prevalence of circulating novel IL-17 secreting Foxp3 expressing CD4+ T cells and defective suppressive function of circulating Foxp3+ regulatory cells support plasticity between Th17 and regulatory T cells in inflammatory bowel disease patients. Inflamm Bowel Dis 2013; 19: 2522-2534, doi: 10.1097/MIB.0b013e3182a85709.
84. Veltkamp C, Anstaett M, Wahl K, Moller S, Gangl S, Bachmann O, et al. Apoptosis of regulatory T lymphocytes is increased in chronic inflammatory bowel disease and reversed by anti-TNFalpha treatment. Gut 2011; 60: 1345-1353, doi: 10.1136/gut.2010.217117.
85. Wang J, Ioan-Facsinay A, van d, V, Huizinga TW, Toes R.E. Transient expression of FOXP3 in human activated nonregulatory CD4+ T cells. Eur J Immunol 2007; 37: 129-138, doi: 10.1002/eji.200636435.
86. Horwitz DA, Zheng SG, Gray J.D. Natural and TGF-betainduced Foxp3(+)CD4(+) CD25(+) regulatory T cells are not mirror images of each other. Trends Immunol 2008; 29: 429-435, doi: 10.1016/j.it.2008.06.005.
87. Shevach E.M. Mechanisms of foxp3+ T regulatory cellmediated suppression. Immunity 2009; 30: 636-645, doi: 10.1016/j.immuni.2009.04.010.
88. Huber S, Gagliani N, Esplugues E, O'Connor W Jr, Huber FJ, Chaudhry A, et al. Th17 cells express interleukin-10 receptor and are controlled by Foxp3(-) and Foxp3+ regulatory CD4+ T cells in an interleukin-10-dependent manner. Immunity 2011; 34: 554-565, doi: 10.1016/j.immuni.2011.01.020.
89. Jeon SG, Kayama H, Ueda Y, Takahashi T, Asahara T, Tsuji H, et al. Probiotic Bifidobacterium breve induces IL-10-producing Tr1 cells in the colon. PLoS Pathog 2012; 8: e1002714, doi: 10.1371/journal.ppat.1002714.
90. Round JL, Mazmanian S.K. Inducible Foxp3+ regulatory Tcell development by a commensal bacterium of the intestinal microbiota. Proc Natl Acad Sci U S A 2010; 107: 12204-12209, doi: 10.1073/pnas.0909122107.